Uncategorized Archives - Corcept Therapeutics

Protected: The Design of MOMENTUM: A Prospective Study of the Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension

June 6, 2025

There is no excerpt because this is a protected post.

Site Options

March 14, 2024

site-options

Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

January 13, 2023

• •

Effect of Miricorilant, a Selective Glucocorticoid Receptor Modulator, on Olanzapine-Associated Weight Gain in Healthy Subjects: A Proof-of-Concept Study

August 18, 2021

• •

A Double-Blind, Randomized, Placebo-Controlled Phase 3 Study to Assess the Ef cacy and Safety of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Patients With Hypercortisolism Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia

September 4, 2020

• •

IChiodini ECE2020-1

September 4, 2020

• •

AGreenstein ECE2020-2

September 4, 2020

• •

ASCO2020-1

May 29, 2020

• •

© 2024 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Your Privacy Choices